You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFludrocortisone
Accession NumberDB00687  (APRD00756, DB02478)
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic mineralocorticoid with anti-inflammatory activity. [PubChem]
Structure
Thumb
Synonyms
9alpha-FLUOROCORTISOL
Fludrocortison
Fludrocortisona
Fludrocortisone
Fludrocortisonum
Fluohydrocortisone
External Identifiers
  • StC 1400
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlorinefTablet0.1 mgOralPaladin Labs Inc1995-12-31Not applicableCanada
Florinef Acetate 0.1mgTablet.1 mgOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1958-12-311997-08-14Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fludrocortisone AcetateTablet.1 mg/1OralAmerican Health Packaging2008-05-09Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralImpax Generics2002-03-18Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralREMEDYREPACK INC.2011-10-032016-11-22Us
Fludrocortisone AcetateTablet.1 mg/1OralPd Rx Pharmaceuticals, Inc.2003-02-14Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralWest ward Pharmaceutical Corp2011-07-22Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralAv Pak2011-08-01Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralCardinal Health2008-05-09Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-30Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralPhysicians Total Care, Inc.2005-10-06Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralTeva Pharmaceuticals Usa, Inc.2003-02-14Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralAv Kare, Inc.2002-03-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdixoneGenopharm
AstoninMerck
CortineffPolfa Pabianice
Florinef AcetaatBristol-Myers Squibb
FlorinefeBristol-Myers Squibb
FludrocortisonBristol-Myers Squibb
LonikanMerck
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fludrocortisone Acetate
Thumb
  • InChI Key: SYWHXTATXSMDSB-GSLJADNHSA-N
  • Monoisotopic Mass: 422.210466929
  • Average Mass: 422.487
DBSALT000659
Categories
UNIIU0476M545B
CAS number127-31-1
WeightAverage: 380.4504
Monoisotopic: 380.199902243
Chemical FormulaC21H29FO5
InChI KeyAAXVEMMRQDVLJB-BULBTXNYSA-N
InChI
InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
IUPAC Name
(1R,2S,10S,11S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Pharmacology
IndicationFor partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
Structured Indications
PharmacodynamicsFludrocortisone is a synthetic adrenocortical steroid possessing very potent mineralocorticoid properties and high glucocorticoid activity. It is indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome. The physiologic action of fludrocortisone acetate is similar to that of hydrocortisone. However, the effects of fludrocortisone acetate, particularly on electrolyte balance, but also on carbohydrate metabolism, are considerably heightened and prolonged. Mineralocorticoids act on the distal tubules of the kidney to enhance the reabsorption of sodium ions from the tubular fluid into the plasma; they increase the urinary excretion of both potassium and hydrogen ions.
Mechanism of actionFludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of the mineralocorticoid receptor by fludrocortisone) in turn causes an increase in ion and water transport and thus raises extracellular fluid volume and blood pressure and lowers potassium levels.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mineralocorticoid receptorProteinyes
agonist
HumanP08235 details
Glucocorticoid receptorProteinunknown
agonist
HumanP04150 details
Androgen receptorProteinunknown
agonist
HumanP10275 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingHigh
Metabolism

Hepatic, some renal.

Route of eliminationNot Available
Half life3.5 hours
ClearanceNot Available
ToxicityEffects of overexposure include irritation, cardiac edema, increased blood volume, hypertension, cardiac arrhythmias, enlargement of the heart, headaches, and weakness of the extremities.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with 1,10-Phenanthroline.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Fludrocortisone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fludrocortisone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Fludrocortisone.Withdrawn
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Fludrocortisone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fludrocortisone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fludrocortisone.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Fludrocortisone.Experimental
AldesleukinFludrocortisone may decrease the antineoplastic activities of Aldesleukin.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Fludrocortisone.Approved
ALT-110The risk or severity of adverse effects can be increased when Fludrocortisone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fludrocortisone.Approved
AmiodaroneThe serum concentration of Fludrocortisone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BFludrocortisone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fludrocortisone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fludrocortisone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fludrocortisone.Approved, Investigational
AprepitantThe serum concentration of Fludrocortisone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Fludrocortisone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fludrocortisone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fludrocortisone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fludrocortisone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Fludrocortisone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fludrocortisone.Approved, Investigational
BazedoxifeneThe serum concentration of Fludrocortisone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Fludrocortisone.Investigational
BendroflumethiazideFludrocortisone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fludrocortisone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fludrocortisone.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fludrocortisone.Investigational
Bismuth SubcitrateThe bioavailability of Fludrocortisone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Fludrocortisone can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fludrocortisone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fludrocortisone.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Fludrocortisone.Withdrawn
BumetanideFludrocortisone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fludrocortisone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Fludrocortisone can be decreased when combined with Calcium carbonate.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fludrocortisone.Approved
CarbamazepineThe serum concentration of Fludrocortisone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fludrocortisone.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Fludrocortisone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Fludrocortisone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fludrocortisone.Approved, Investigational
CeritinibFludrocortisone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fludrocortisone.Approved, Vet Approved
ChlorothiazideFludrocortisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fludrocortisone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fludrocortisone.Approved
ChlorthalidoneFludrocortisone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Fludrocortisone.Experimental
CinoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Fludrocortisone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fludrocortisone.Approved
CobicistatThe serum concentration of Fludrocortisone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Fludrocortisone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fludrocortisone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fludrocortisone.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Fludrocortisone.Investigational
DarunavirThe serum concentration of Fludrocortisone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Fludrocortisone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Fludrocortisone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Fludrocortisone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fludrocortisone.Approved, Vet Approved
DienestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fludrocortisone.Approved
DihydrotestosteroneFludrocortisone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fludrocortisone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Fludrocortisone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fludrocortisone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Fludrocortisone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Fludrocortisone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Edrophonium.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fludrocortisone.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Fludrocortisone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fludrocortisone.Approved
EstradiolThe serum concentration of Fludrocortisone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Fludrocortisone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Fludrocortisone can be increased when it is combined with Estrone.Approved
Etacrynic acidFludrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fludrocortisone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Fludrocortisone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fludrocortisone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fludrocortisone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fludrocortisone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fludrocortisone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Fludrocortisone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fludrocortisone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fludrocortisone.Approved
FenthionThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fenthion.Vet Approved
FingolimodFludrocortisone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fludrocortisone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fludrocortisone.Vet Approved
FluoxymesteroneFludrocortisone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fludrocortisone.Approved, Investigational
FosaprepitantThe serum concentration of Fludrocortisone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fludrocortisone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideFludrocortisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fludrocortisone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Fludrocortisone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Fludrocortisone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Fludrocortisone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Fludrocortisone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Fludrocortisone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Fludrocortisone.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fludrocortisone.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fludrocortisone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Fludrocortisone.Investigational
HexestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fludrocortisone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Fludrocortisone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fludrocortisone.Approved, Investigational
HydrochlorothiazideFludrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFludrocortisone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fludrocortisone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fludrocortisone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fludrocortisone.Approved
IdelalisibThe serum concentration of Fludrocortisone can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Fludrocortisone.Approved
IndapamideFludrocortisone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fludrocortisone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fludrocortisone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Fludrocortisone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fludrocortisone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Fludrocortisone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Fludrocortisone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Fludrocortisone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Fludrocortisone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fludrocortisone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Fludrocortisone.Approved
IsoflurophateThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fludrocortisone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fludrocortisone.Withdrawn
ItraconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fludrocortisone.Experimental
KetoconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fludrocortisone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fludrocortisone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Fludrocortisone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Fludrocortisone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fludrocortisone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fludrocortisone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fludrocortisone.Approved
LumacaftorThe serum concentration of Fludrocortisone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fludrocortisone.Approved, Investigational
MagaldrateThe bioavailability of Fludrocortisone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fludrocortisone.Approved
Magnesium TrisilicateThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fludrocortisone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fludrocortisone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fludrocortisone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fludrocortisone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fludrocortisone.Approved
MestranolThe serum concentration of Fludrocortisone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fludrocortisone.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone.Approved
MethallenestrilThe serum concentration of Fludrocortisone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFludrocortisone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneFludrocortisone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneFludrocortisone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Fludrocortisone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Fludrocortisone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Fludrocortisone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
MitotaneThe serum concentration of Fludrocortisone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fludrocortisone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fludrocortisone.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fludrocortisone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fludrocortisone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fludrocortisone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fludrocortisone.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fludrocortisone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fludrocortisone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Fludrocortisone.Investigational
NefazodoneThe serum concentration of Fludrocortisone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fludrocortisone.Approved
NevirapineThe serum concentration of Fludrocortisone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fludrocortisone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fludrocortisone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fludrocortisone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fludrocortisone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fludrocortisone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fludrocortisone.Vet Approved
OxandroloneFludrocortisone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fludrocortisone.Approved
OxymetholoneFludrocortisone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fludrocortisone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fludrocortisone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Fludrocortisone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Fludrocortisone.Approved, Withdrawn
PhenobarbitalThe serum concentration of Fludrocortisone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fludrocortisone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fludrocortisone.Approved, Vet Approved
PhenytoinThe serum concentration of Fludrocortisone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludrocortisone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Fludrocortisone.Approved, Investigational
PiretanideFludrocortisone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fludrocortisone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fludrocortisone.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Fludrocortisone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFludrocortisone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
PrimidoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Fludrocortisone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fludrocortisone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fludrocortisone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Quinestrol.Approved
QuinethazoneFludrocortisone may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Fludrocortisone.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fludrocortisone.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fludrocortisone.Experimental, Investigational
RifabutinThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Fludrocortisone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fludrocortisone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Fludrocortisone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Fludrocortisone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Fludrocortisone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fludrocortisone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fludrocortisone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fludrocortisone.Approved
SaquinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Fludrocortisone.Approved
SecoisolariciresinolThe serum concentration of Fludrocortisone can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fludrocortisone.Approved, Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludrocortisone.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Fludrocortisone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fludrocortisone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Fludrocortisone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fludrocortisone.Investigational
St. John's WortThe serum concentration of Fludrocortisone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololFludrocortisone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fludrocortisone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fludrocortisone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fludrocortisone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Fludrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fludrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludrocortisone.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fludrocortisone.Approved
TelithromycinThe serum concentration of Fludrocortisone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fludrocortisone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fludrocortisone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fludrocortisone.Approved
TestosteroneFludrocortisone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Fludrocortisone is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Fludrocortisone.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fludrocortisone.Approved
TiboloneThe serum concentration of Fludrocortisone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fludrocortisone.Investigational
TofacitinibFludrocortisone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Fludrocortisone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Fludrocortisone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fludrocortisone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fludrocortisone.Approved
TorasemideFludrocortisone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fludrocortisone.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Fludrocortisone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Trichlorfon.Vet Approved
TrichlormethiazideFludrocortisone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fludrocortisone.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Fludrocortisone.Withdrawn
TrovafloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fludrocortisone.Investigational, Withdrawn
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fludrocortisone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Fludrocortisone.Approved, Investigational
VoriconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinFludrocortisone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fludrocortisone.Approved
ZeranolThe serum concentration of Fludrocortisone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fludrocortisone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fludrocortisone.Withdrawn
Food Interactions
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Take with food to reduce irritation.
References
Synthesis Reference

U.S. Patent 2,957,013

General ReferencesNot Available
External Links
ATC CodesS02CA07S01CA06S03CA05H02AA02
AHFS Codes
  • 68:04.00
PDB Entries
FDA labelNot Available
MSDSDownload (73 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9731
Caco-2 permeable+0.8415
P-glycoprotein substrateSubstrate0.7911
P-glycoprotein inhibitor INon-inhibitor0.8385
P-glycoprotein inhibitor IINon-inhibitor0.9351
Renal organic cation transporterNon-inhibitor0.7774
CYP450 2C9 substrateNon-substrate0.8799
CYP450 2D6 substrateNon-substrate0.909
CYP450 3A4 substrateSubstrate0.7138
CYP450 1A2 substrateNon-inhibitor0.9306
CYP450 2C9 inhibitorNon-inhibitor0.9023
CYP450 2D6 inhibitorNon-inhibitor0.9201
CYP450 2C19 inhibitorNon-inhibitor0.9285
CYP450 3A4 inhibitorNon-inhibitor0.8772
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.903
Ames testNon AMES toxic0.8895
CarcinogenicityNon-carcinogens0.9479
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.1686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9591
hERG inhibition (predictor II)Inhibitor0.5213
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Barr laboratories inc
  • Impax laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral0.1 mg
TabletOral.1 mg
TabletOral.1 mg/1
Prices
Unit descriptionCostUnit
Fludrocortisone acetate powder73.14USD g
Florinef acetate 0.1 mg tablet1.49USD tablet
Fludrocortisone Acetate 0.1 mg tablet0.81USD tablet
Fludrocortisone 0.1 mg tablet0.75USD tablet
Florinef 0.1 mg Tablet0.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility140 mg/L (at 25 °C)MERCK INDEX (1996)
logP1.67HANSCH,C ET AL. (1995)
logS-3.43ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.224 mg/mLALOGPS
logP1.35ALOGPS
logP1.32ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity96.93 m3·mol-1ChemAxon
Polarizability39.6 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Otte C, Jahn H, Yassouridis A, Arlt J, Stober N, Maass P, Wiedemann K, Kellner M: The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sci. 2003 Aug 22;73(14):1835-45. [PubMed:12888122 ]
  2. Oelkers W, Buchen S, Diederich S, Krain J, Muhme S, Schoneshofer M: Impaired renal 11 beta-oxidation of 9 alpha-fluorocortisol: an explanation for its mineralocorticoid potency. J Clin Endocrinol Metab. 1994 Apr;78(4):928-32. [PubMed:8157723 ]
  3. Young MJ, Funder JW: Mineralocorticoids, salt, hypertension: effects on the heart. Steroids. 1996 Apr;61(4):233-5. [PubMed:8733007 ]
  4. Kingsley-Kallesen M, Mukhopadhyay SS, Wyszomierski SL, Schanler S, Schutz G, Rosen JM: The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. Mol Endocrinol. 2002 Sep;16(9):2008-18. [PubMed:12198239 ]
  5. Buckley TM, Mullen BC, Schatzberg AF: The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology. 2007 Sep-Nov;32(8-10):859-64. Epub 2007 Jul 30. [PubMed:17666187 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Trune DR, Kempton JB: Low dose combination steroids control autoimmune mouse hearing loss. J Neuroimmunol. 2010 Dec 15;229(1-2):140-5. doi: 10.1016/j.jneuroim.2010.07.026. Epub 2010 Aug 30. [PubMed:20800906 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:
AR
Uniprot ID:
P10275
Molecular Weight:
98987.9 Da
References
  1. Krishnan AV, Zhao XY, Swami S, Brive L, Peehl DM, Ely KR, Feldman D: A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology. 2002 May;143(5):1889-900. [PubMed:11956172 ]
  2. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P: Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem. 2002 Mar 28;45(7):1439-46. [PubMed:11906285 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23